<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">myrwd</journal-id><journal-title-group><journal-title xml:lang="ru">Реальная клиническая практика: данные и доказательства</journal-title><trans-title-group xml:lang="en"><trans-title>Real-World Data &amp; Evidence</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2782-3784</issn><publisher><publisher-name>Publishing House OKI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2782-3784-myrwd-101</article-id><article-id custom-type="edn" pub-id-type="custom">ZTDIKD</article-id><article-id custom-type="elpub" pub-id-type="custom">myrwd-140</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕТОДОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>METHODOLOGY</subject></subj-group></article-categories><title-group><article-title>Разработка биостатистической методологии для анализа данных реальной клинической практики при оценке биологически активных добавок</article-title><trans-title-group xml:lang="en"><trans-title>Development and validation of a biostatistical framework for consistent evaluation of food supplement efficacy and safety using real-world data</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-3178-0424</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Идриса</surname><given-names>К.</given-names></name><name name-style="western" xml:lang="en"><surname>Kiryowa</surname><given-names>I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Идриса Кирёва - магистрант</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Kiryowa Idrisa - MSc, Student</p><p>St. Petersburg</p></bio><email xlink:type="simple">408079@edu.itmo.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-5112-3960</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Холопов</surname><given-names>Р. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kholopov</surname><given-names>R. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Холопов Руслан Александрович - студент</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Ruslan A. Kholopov - student</p><p>St. Petersburg</p></bio><email xlink:type="simple">kholopovruslan@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-4454-2782</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драгунс</surname><given-names>В.</given-names></name><name name-style="western" xml:lang="en"><surname>Draguns</surname><given-names>V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Драгунс Виталий - зам. генерального директора</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Vitaly Draguns - deputy general director</p><p>St. Petersburg</p></bio><email xlink:type="simple">vdraguns@x7cpr.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1204-5041</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Булкран</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Boulkrane</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Булкран Мохамед Саид - доцент</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Mohamed Said Boulkrane - Associate Professor</p><p>St. Petersburg</p></bio><email xlink:type="simple">mboulkrane@itmo.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Национальный исследовательский университет ИТМО»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>ITMO University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Санкт-Петербургский колледж телекоммуникаций им. Э.Т. Кренкеля структурное подразделение ФГБОУ ВО «Санкт-Петербургский государственный университет телекоммуникаций им. проф. М.А. Бонч-Бруевича»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>St. Petersburg College of Telecommunications named after E.T. Krenkel is a structural division of the St. Petersburg State University of Telecommunications named after prof. M.A. Bonch-Bruevich</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ООО «Экс Севен Ресеч»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>X7 Research LLC</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>30</day><month>06</month><year>2026</year></pub-date><volume>6</volume><issue>2</issue><fpage>19</fpage><lpage>32</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Идриса К., Холопов Р.А., Драгунс В., Булкран М.С., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Идриса К., Холопов Р.А., Драгунс В., Булкран М.С.</copyright-holder><copyright-holder xml:lang="en">Kiryowa I., Kholopov R.A., Draguns V., Boulkrane M.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.myrwd.ru/jour/article/view/140">https://www.myrwd.ru/jour/article/view/140</self-uri><abstract><sec><title>Цель</title><p>Цель. Разработка и валидация гибридной биостатистической методологии для генерации доказательств, основанных на данных реальной клинической практики (RWE) при оценке эффективности и безопасности биологически активных добавок (БАД).</p></sec><sec><title>Методы</title><p>Методы. Предложенная концепция объединяет методы причинно-следственного вывода (IPTW) с ансамблевыми методами машинного обучения (CatBoost, Random Forest) и множественным восполнением пропущенных данных (MICE). Валидация проводилась на двух пилотных неинтервенционных исследованиях (N=249) и высокоразмерном синтетическом наборе данных (N=6000) с уровнем пропусков до 83,33%. Для оценки соотношения польза–риск использовалась многокритериальная Парето-оптимизация.</p></sec><sec><title>Результаты</title><p>Результаты. Применение IPTW позволило достичь стандартизированной разницы средних (SMD) &lt;0,10 по всем исходным характеристикам. Регрессионная модель эффективности достигла R² = 0,3596. Модель классификации безопасности на основе CatBoost после оптимизации порога классификации показала PRAUC = 0,123 и F1-меру = 0,218, что позволило выявить скрытые сигналы нежелательных явлений (например, 12,47% для магния 400 мг). Парето-оптимизация обеспечила объективное сравнение профилей БАД без субъективного взвешивания показателей.</p></sec><sec><title>Заключение</title><p>Заключение. Разработанная методология повышает согласованность и надёжность пострегистрационной оценки БАД на основе RWD и может быть использована регуляторными органами (FDA, EFSA, Росздравнадзор РФ).</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective. To develop and validate a hybrid biostatistical methodology for generating Real-World Evidence (RWE) to assess the efficacy and safety of food supplements.</p></sec><sec><title>Methods</title><p>Methods. The proposed framework integrates causal inference techniques (Inverse Probability of Treatment Weighting, IPTW) with ensemble machine learning methods (CatBoost, Random Forest) and Multiple Imputation by Chained Equations (MICE). Validation was performed using two pilot non-interventional studies (N=249) and a high-dimensional synthetic dataset (N=6000) with missingness up to 83.33%. Multi-objective Pareto optimization was applied for benefit–risk assessment. </p></sec><sec><title>Results</title><p>Results. IPTW achieved a standardized mean difference (SMD) &lt;0.10 across all baseline covariates. The efficacy regression model attained an R² of 0.3596. The CatBoost-based safety classification model, after threshold optimization, achieved a PRfor Magnesium 400 mg). Pareto optimization provided an objective comparison of supplement profiles without subjective AUC of 0.123 and an F1-score of 0.218, enabling the detection of latent adverse event signals (e.g., 12.47% indicator weighting.</p></sec><sec><title>Conclusion</title><p>Conclusion. The developed methodology improves the consistency and reliability of post-market supplement evaluation using RWD and can support regulatory activities of organizations such as Food and Drug Administration, European Food Safety Authority, and Roszdravnadzor RF.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>доказательства</kwd><kwd>основанные на данных реальной клинической практики</kwd><kwd>пищевые добавки</kwd><kwd>причинно-следственный вывод</kwd><kwd>машинное обучение</kwd><kwd>Парето-оптимизация</kwd><kwd>обнаружение сигналов</kwd><kwd>биостатистика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>real-world evidence</kwd><kwd>food supplements</kwd><kwd>causal inference</kwd><kwd>machine learning</kwd><kwd>Pareto optimization</kwd><kwd>signal detection</kwd><kwd>biostatistics</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Abdel-Tawab M. Do We Need Plant Food Supplements? A Critical Examination of Quality, Safety, Efficacy, and Necessity for a New Regulatory Framework. Planta Med . 2018 Apr;84(6-07):372393. doi: 10.1055/s-0043-123764.</mixed-citation><mixed-citation xml:lang="en">Abdel-Tawab M. Do We Need Plant Food Supplements? A Critical Examination of Quality, Safety, Efficacy, and Necessity for a New Regulatory Framework. Planta Med . 2018 Apr;84(6-07):372393. doi: 10.1055/s-0043-123764.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Chodankar D. Introduction to real-world evidence studies. Perspect Clin Res . 2021 JulSep;12(3):171-174. doi: 10.4103/picr.picr_62_21.</mixed-citation><mixed-citation xml:lang="en">Chodankar D. Introduction to real-world evidence studies. Perspect Clin Res . 2021 JulSep;12(3):171-174. doi: 10.4103/picr.picr_62_21.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Berger ML, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and/ or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf . 2017 Sep;26(9):1033-1039. doi: 10.1002/pds.4297.</mixed-citation><mixed-citation xml:lang="en">Berger ML, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and/ or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf . 2017 Sep;26(9):1033-1039. doi: 10.1002/pds.4297.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Justo N, Espinoza MA, Ratto B, et al. Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America. Value Health . 2019 Jun;22(6):739-749. doi: 10.1016/j.jval.2019.01.014.</mixed-citation><mixed-citation xml:lang="en">Justo N, Espinoza MA, Ratto B, et al. Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America. Value Health . 2019 Jun;22(6):739-749. doi: 10.1016/j.jval.2019.01.014.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">FDA UF&amp; DA. Framework for FDA's Real-World Evidence Program. U.S. Department of Health and Human Services; 2018 Feb.</mixed-citation><mixed-citation xml:lang="en">FDA UF&amp; DA. Framework for FDA's Real-World Evidence Program. U.S. Department of Health and Human Services; 2018 Feb.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Sahab B, Leviton A, Loddenkemper T, et al. Biases in Electronic Health Records Data for Generating Real-World Evidence: An Overview. J Healthc Inform Res . 2023 Nov 14;8(1):121-139. doi: 10.1007/s41666-023-00153-2.</mixed-citation><mixed-citation xml:lang="en">Al-Sahab B, Leviton A, Loddenkemper T, et al. Biases in Electronic Health Records Data for Generating Real-World Evidence: An Overview. J Healthc Inform Res . 2023 Nov 14;8(1):121-139. doi: 10.1007/s41666-023-00153-2.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Blonde L, Khunti K, Harris SB, et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy . 2018 Nov;35(11):1763-1774. DOI: 10.1007/s12325-018-0805-y.</mixed-citation><mixed-citation xml:lang="en">Blonde L, Khunti K, Harris SB, et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy . 2018 Nov;35(11):1763-1774. DOI: 10.1007/s12325-018-0805-y.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Prokhorenkova L, Gusev G, Vorobev A, Dorogush AV, Gulin A. CatBoost: unbiased boosting with categorical features. ArXiv Cornell Univ . 2017 Jun;31:6639-49. DOI: 10.48550/arxiv.1706.09516</mixed-citation><mixed-citation xml:lang="en">Prokhorenkova L, Gusev G, Vorobev A, Dorogush AV, Gulin A. CatBoost: unbiased boosting with categorical features. ArXiv Cornell Univ . 2017 Jun;31:6639-49. DOI: 10.48550/arxiv.1706.09516</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika . 1983 Jan;70(1):41-55. DOI: 10.1093/biomet/70.1.41.</mixed-citation><mixed-citation xml:lang="en">Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika . 1983 Jan;70(1):41-55. DOI: 10.1093/biomet/70.1.41.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cristoforetti R, Süss P, Becher T, Wahl N. Trading robustness: a scenario-free approach to robust Multi-Criteria Optimization for Treatment Planning. ArXiv Cornell Univ . 2025 Oct. DOI: 10.48550/arxiv.2510.12519</mixed-citation><mixed-citation xml:lang="en">Cristoforetti R, Süss P, Becher T, Wahl N. Trading robustness: a scenario-free approach to robust Multi-Criteria Optimization for Treatment Planning. ArXiv Cornell Univ . 2025 Oct. DOI: 10.48550/arxiv.2510.12519</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Tsionas EG. Multi-objective optimization using statistical models. Eur J Oper Res . 2019 Jan; 276(1):364-78. DOI: 10.1016/j.ejor.2018.12.042.</mixed-citation><mixed-citation xml:lang="en">Tsionas EG. Multi-objective optimization using statistical models. Eur J Oper Res . 2019 Jan; 276(1):364-78. DOI: 10.1016/j.ejor.2018.12.042.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Baumeister SE, Leiva-Escobar I, Demmer RT, et al. Target Trial Emulation in Observational Research-Strengths, Limitations, and Methodological Considerations. J Periodontal Res . 2026 Mar 6. doi: 10.1111/jre.70095.</mixed-citation><mixed-citation xml:lang="en">Baumeister SE, Leiva-Escobar I, Demmer RT, et al. Target Trial Emulation in Observational Research-Strengths, Limitations, and Methodological Considerations. J Periodontal Res . 2026 Mar 6. doi: 10.1111/jre.70095.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kaufmann NC, Pereira PL. Real-World Evidence: Better than Nothing or the Future? A Perspective on Clinical Evidence Generation in Interventional Oncology. Cardiovasc Intervent Radiol . 2026 May; 49(5):854-861. doi: 10.1007/s00270-025-04179-4.</mixed-citation><mixed-citation xml:lang="en">Kaufmann NC, Pereira PL. Real-World Evidence: Better than Nothing or the Future? A Perspective on Clinical Evidence Generation in Interventional Oncology. Cardiovasc Intervent Radiol . 2026 May; 49(5):854-861. doi: 10.1007/s00270-025-04179-4.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Khaowroongrueng V, Kim TE, Park SI, Shin KH. Application of Real-World Evidence to Support FDA Regulatory Decision Making. AAPS J 2025 May 28;27(4):98. doi: 10.1208/s12248-02501082-1.</mixed-citation><mixed-citation xml:lang="en">Khaowroongrueng V, Kim TE, Park SI, Shin KH. Application of Real-World Evidence to Support FDA Regulatory Decision Making. AAPS J 2025 May 28;27(4):98. doi: 10.1208/s12248-02501082-1.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lin X, Tarp JM, Evans RJ. Data fusion for efficiency gain in ATE estimation: A practical review with simulations. arXiv (Cornell University) [Internet]. Cornell University; 2024. Available from: http://arxiv.org/abs/2407.01186 DOI: 10.485 50/arxiv.2407.01186</mixed-citation><mixed-citation xml:lang="en">Lin X, Tarp JM, Evans RJ. Data fusion for efficiency gain in ATE estimation: A practical review with simulations. arXiv (Cornell University) [Internet]. Cornell University; 2024. Available from: http://arxiv.org/abs/2407.01186 DOI: 10.485 50/arxiv.2407.01186</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Yan, C., Yan, Y., Wan, Z. et al. A Multifaceted benchmarking of synthetic electronic health record generation models. Nat Commun 2022;13:7609. Doi: 10.1038/s41467-022-35295-1</mixed-citation><mixed-citation xml:lang="en">Yan, C., Yan, Y., Wan, Z. et al. A Multifaceted benchmarking of synthetic electronic health record generation models. Nat Commun 2022;13:7609. Doi: 10.1038/s41467-022-35295-1</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Azur M, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res 2011 Feb 24;20(1):40–49. doi: 10.1002/mpr.329.</mixed-citation><mixed-citation xml:lang="en">Azur M, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res 2011 Feb 24;20(1):40–49. doi: 10.1002/mpr.329.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Zang C, Zhang H, Xu J, et al. High-throughput target trial emulation for Alzheimer's disease drug repurposing with real-world data. Nat Commun 2023 Dec 11;14(1):8180. doi: 10.1038/s41467023-43929-1.</mixed-citation><mixed-citation xml:lang="en">Zang C, Zhang H, Xu J, et al. High-throughput target trial emulation for Alzheimer's disease drug repurposing with real-world data. Nat Commun 2023 Dec 11;14(1):8180. doi: 10.1038/s41467023-43929-1.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Bechny M, Kishi A, Fiorillo L, et al. Novel Digital Markers of Sleep Dynamics: A CausalInference Approach Revealing Age and Gender Phenotypes in Obstructive Sleep Apnea. Research Square 2024. DOI: 10.21203/rs.3.rs-5317875/v1.</mixed-citation><mixed-citation xml:lang="en">Bechny M, Kishi A, Fiorillo L, et al. Novel Digital Markers of Sleep Dynamics: A CausalInference Approach Revealing Age and Gender Phenotypes in Obstructive Sleep Apnea. Research Square 2024. DOI: 10.21203/rs.3.rs-5317875/v1.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Yin H, Li XR, Gao Y. Relative Euclidean Distance With Application to TOPSIS and Estimation Performance Ranking. IEEE Trans Syst Man Cybern Syst . 2020 Sep;52(2):1052-64. DOI: 10.1109/tsmc.2020.3017814.</mixed-citation><mixed-citation xml:lang="en">Yin H, Li XR, Gao Y. Relative Euclidean Distance With Application to TOPSIS and Estimation Performance Ranking. IEEE Trans Syst Man Cybern Syst . 2020 Sep;52(2):1052-64. DOI: 10.1109/tsmc.2020.3017814.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Mazza A, Chicco G, Russo A, Virjoghe EO. Multi-Objective Distribution Network Reconfiguration Based on Pareto Front Ranking. Intell Ind Syst . 2016 Dec;2(4):287-302. DOI: 10.1007/s40903-016-0065-6.</mixed-citation><mixed-citation xml:lang="en">Mazza A, Chicco G, Russo A, Virjoghe EO. Multi-Objective Distribution Network Reconfiguration Based on Pareto Front Ranking. Intell Ind Syst . 2016 Dec;2(4):287-302. DOI: 10.1007/s40903-016-0065-6.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lazzerini B, Pistolesi F. Multiobjective Personnel Assignment Exploiting Workers' Sensitivity to Risk. IEEE Trans Syst Man Cybern Syst . 2017 Feb;48(8):1267-82. DOI: 10.1109/tsmc.2017.2665349</mixed-citation><mixed-citation xml:lang="en">Lazzerini B, Pistolesi F. Multiobjective Personnel Assignment Exploiting Workers' Sensitivity to Risk. IEEE Trans Syst Man Cybern Syst . 2017 Feb;48(8):1267-82. DOI: 10.1109/tsmc.2017.2665349</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Dang LE, Gruber S, Lee H, et al. A causal roadmap for generating high-quality real-world evidence. Journal of Clinical and Translational Science 2023 ;7(1):e212. DOI: 10.1017/cts.2023.635.</mixed-citation><mixed-citation xml:lang="en">Dang LE, Gruber S, Lee H, et al. A causal roadmap for generating high-quality real-world evidence. Journal of Clinical and Translational Science 2023 ;7(1):e212. DOI: 10.1017/cts.2023.635.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Brantner CL, Chang TH, Nguyen TQ, et al. Methods for Integrating Trials and Non-experimental Data to Examine Treatment Effect Heterogeneity. Stat Sci . 2023 Nov;38(4):640-654. doi: 10.1214/23sts890.</mixed-citation><mixed-citation xml:lang="en">Brantner CL, Chang TH, Nguyen TQ, et al. Methods for Integrating Trials and Non-experimental Data to Examine Treatment Effect Heterogeneity. Stat Sci . 2023 Nov;38(4):640-654. doi: 10.1214/23sts890.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Y, Li J, Li M, Aparasu RR. Application of machine learning in predicting survival outcomes involving real-world data: a scoping review. BMC Med Res Methodol . 2023 Nov 13;23(1):268. doi: 10.1186/s12874-023-02078-1.</mixed-citation><mixed-citation xml:lang="en">Huang Y, Li J, Li M, Aparasu RR. Application of machine learning in predicting survival outcomes involving real-world data: a scoping review. BMC Med Res Methodol . 2023 Nov 13;23(1):268. doi: 10.1186/s12874-023-02078-1.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Reps JM, Garibaldi JM, Aickelin U, et al. Signalling paediatric side effects using an ensemble of simple study designs. Drug Saf . 2014 Mar;37(3): 163-70. doi: 10.1007/s40264-014-0137-z.</mixed-citation><mixed-citation xml:lang="en">Reps JM, Garibaldi JM, Aickelin U, et al. Signalling paediatric side effects using an ensemble of simple study designs. Drug Saf . 2014 Mar;37(3): 163-70. doi: 10.1007/s40264-014-0137-z.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Marzano L, Darwich AS, Tendler S, et al. A novel analytical framework for risk stratification of real-world data using machine learning: A small cell lung cancer study. Clin Transl Sci . 2022 Oct;15(10):2437-2447. doi: 10.1111/cts.13371.</mixed-citation><mixed-citation xml:lang="en">Marzano L, Darwich AS, Tendler S, et al. A novel analytical framework for risk stratification of real-world data using machine learning: A small cell lung cancer study. Clin Transl Sci . 2022 Oct;15(10):2437-2447. doi: 10.1111/cts.13371.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Fatima G, Khan S, Shukla V, et al. Nutraceutical formulations and natural compounds for the management of chronic diseases. Front Nutr . 2025 Oct 15;12:1682590. doi: 10.3389/fnut.2025.1682590.</mixed-citation><mixed-citation xml:lang="en">Fatima G, Khan S, Shukla V, et al. Nutraceutical formulations and natural compounds for the management of chronic diseases. Front Nutr . 2025 Oct 15;12:1682590. doi: 10.3389/fnut.2025.1682590.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Kadro ZO, Chilcoat A, Hill J, et al. Healthcare Professionals' Perspectives on Improving Dietary Supplement Documentation in the Electronic Medical Record: Current Challenges and Opportunities to Enhance Quality of Care and Patient Safety. Glob Adv Integr Med Health . 2023 Dec 19;12:27536130231215029. doi: 10.1177/27536130231215029.</mixed-citation><mixed-citation xml:lang="en">Kadro ZO, Chilcoat A, Hill J, et al. Healthcare Professionals' Perspectives on Improving Dietary Supplement Documentation in the Electronic Medical Record: Current Challenges and Opportunities to Enhance Quality of Care and Patient Safety. Glob Adv Integr Med Health . 2023 Dec 19;12:27536130231215029. doi: 10.1177/27536130231215029.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Rita L, Southern J, Laponogov I, et al. Optimizing Ingredient Substitution Using Large Language Models to Enhance Phytochemical Content in Recipes. ArXiv Cornell Univ . 2024 Sep. DOI: 10.48550/arxiv.2409.08792.</mixed-citation><mixed-citation xml:lang="en">Rita L, Southern J, Laponogov I, et al. Optimizing Ingredient Substitution Using Large Language Models to Enhance Phytochemical Content in Recipes. ArXiv Cornell Univ . 2024 Sep. DOI: 10.48550/arxiv.2409.08792.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
